This study confirmed previously reported loss-of-function alterations in KMT2D/MLL2 (12.9%), CREBBP (6.1%), and NOTCH1 (5.9%), and gain-of-function events and copy number amplifications in MYC (6.0%), MYCL (7.2%), and SOX2 (3.4%) as frequent molecular alterations in SCLC. This evidence concerns the gene KMT2D and small cell lung carcinoma.